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This month, PLoS Genetics is publishing
an article from the company 23andMe
reporting the first genome-wide associa-
tion studies (GWAS) on multiple traits
ascertained by self-reported information
provided through the Internet from over
10,000 participants who pay the company
for providing whole genome genotypes
[1]. The paper passed through scientific
review by a panel of three experts
relatively quickly and is sure to attract
the attention of anyone with freckles, curly
hair, or an aversion to asparagus. Novel
associations are described for four intrin-
sically interesting traits (out of 22 consid-
ered), while known associations with hair
and eye color are replicated in a dynamic
data-gathering context. Additionally, in-
triguing observations on the interaction
between genetic self-knowledge and self-
report of phenotypes are described. The
implications of the successful application
of this Internet-enabled approach to
GWAS research were considered to be
more than sufficient to warrant publica-
tion in the journal.
However, publication was delayed for six
months while the editors sought a variety of
opinions on three issues: ethical review,
consent, and data access. Anyone who has
read Rebecca Skloot’s The Immortal Life of
Henrietta Lacks [2] will be sensitive to the
ongoing ethical and moral concerns sur-
rounding consent and research withhuman
samples. The editors of PLoS Genetics
decided to proceed after satisfying ourselves
on two major points, namely that the
participants were not coerced to participate
in the study in any way, and they were
clearly aware that their samples would be
used for genetic research. Recognizing that
institutional review is an imperfect process
and that the complexities raised by GWAS
are not readily resolved, we call for a
concerted effort on the part of granting
agencies, scientists, review boards, and the
public communities they serve to standard-
izeprocessesandproceduresofconsentand
review of human genomic research. It also
needs to be stated that the Editor-in-Chief,
Professor Greg Barsh, is a potential consul-
tant to 23andMe, and so recused himself
from all dealings with this paper prior to
acceptance.
Institutional Review
The first issue that attracted our attention
was that the initial submission lacked a
document indicating that the study had
passed review by an institutional review
board (IRB). The authors responded by
submitting a report,obtained afterthe initial
round of review, from the Association for
the Accreditation of Human Research
ProtectionPrograms(AAHRPP)–accredited
company Independent Review Consulting,
Inc. (IRC: San Anselmo, CA), exempting
them from review on the basis that their
activity is ‘‘not human subjects research.’’
On the face of it, this seems preposterous,
but on further review, this decision follows
not uncommon practices by most scientists
and institutional review boards, both aca-
demic and commercial, and is based on a
guidance statement from the United States
Department of Health and Human Servic-
es’ Office of Human Research Protection
(http://www.hhs.gov/ohrp/humansubjects/
guidance/cdebiol.htm). Specifically (and as
documented in part C2 of the IRC report),
there are two criteria that must be met in
order to determine that a study involves
human subjects research: will the investi-
gators obtain the data through intervention
or interaction with the participants, and
will the identity of the subject be readily
ascertainedbytheinvestigatororassociated
with the information. For the 23andMe
study, the answer to both tests was ‘‘no,’’
ostensibly because there was never any
interpersonal contact between investigator
and participant (that is, data and samples
are provided without participants meeting
any investigator), and the participant
names are anonymous with respect to the
data seen by the investigators. It follows
from the logic of the IRC review, in
accordance with the OHRP guidance
documents, that this study does not involve
human subjects research.
It is not the policy of PLoS Genetics to
routinely delve into the specifics of indi-
vidual IRB determinations, which we
assume provide reasonable oversight of
the process by which human samples and
data are obtained. In this case, concerns
were raised that a commercial IRB, paid
for their opinion by the company, is not in
a position of independence, but this is
standard practice in the pharmaceutical
and biotechnical industries, and similar
concerns can be raised over the indepen-
dence of University boards considering
multi-million–dollar studies. Furthermore,
although several of the authors have
academic affiliations, we obtained express
certification that the study was not per-
formed under the auspices of their Uni-
versities, and we did not feel that review by
an academic IRB was necessarily appro-
priate. Finally, we were also mindful of the
fact that this is a minimal-risk study that
would almost certainly pass institutional
review contingent on the adequacy of the
consent process, so next focused our
attention on that aspect.
Consent
Participants in the 23andMe study are
required to sign an extensive ‘‘consent and
legal agreement’’ document (see https://
www.23andme.com/about/consent/), and
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mation about the studies. Participation is
without doubt voluntary as it is participant-
initiated. The consent document states
clearly that the services provided by
23andMe are not designed to diagnose
disease or intended to provide medical
advice and states the risks associated with
obtaining unanticipated self-knowledge. A
section on research indicates that samples
will be used to advance the field of genetics
and human health and to improve and
expand future services, but also notes that
prior to embarking on collaborative part-
nerships with other investigators and orga-
nizations additional individual consent will
be sought before individual-level data is
shared. However, we had a number of
concerns regarding the consent, particular-
ly pertaining to the use of technical jargon
in the document that may limit under-
standing, ambiguity over what data partic-
ipants understand will be published, and
whether standard legal requirements are
met by the document.
PLoS Genetics sought expert opinion and
engaged in discussions among the editors.
We found broad agreement that if formal
review of the document had been carried
out under the auspices of an IRB, changes
are likely to have led to an improved
consent process. Some serious objections
were raised, and these varied across
reviewers. A major one related to the
definition of collaboration and the listing
of one of the senior authors solely as an
affiliate of Columbia University, implying
that he was a collaborator and hence that
independent consent may have been
required. However, the authors have
confirmed that his participation was as a
consultant to 23andMe, with a core role in
study planning and analysis. On balance,
the editors of PLoS Genetics were satisfied
that the document meets minimal legal
requirements and that there is sufficient
information for participants to realize that
they are participating in genetic research
(if not human subjects research), that there
are associated risks, and that study con-
clusions will be published with every effort
made to protect participant anonymity
and restrict access to their own genotypes.
We then had to decide whether to
require re-consent of over 3,000 partici-
pants. Practically, this would be a formida-
ble task, although, given the Web-based
nature of the study,automated contactwith
the vast majority of participants would be
possible. Furthermore, a formal rewriting
of the document that satisfied all possible
concerns, given the diversity of opinion we
encountered, would take considerable time.
Consequently, we elected to require that
the authors address our concerns about
their consent process moving forward, and
they now indicate in the published paper
that IRC has since been fully engaged as a
formal IRB. We also note that the experi-
ence of 23andMe reflects an unfortunate
loophole that applies to all research with
human samples that is not, as above,
formally designated to be ‘‘human subjects
research.’’ For situations in which a study
does not meet the aforementioned criteria
but obtaining a consent form would still be
desirable, there are no guidelines or policy
with regard to how such a consent form
should be developed and reviewed in an
ethically responsible manner.
Data Access
Our third major issue concerned data
access. The desire to promote open access
to data is complicated by the evolving
difficulty in protecting the identity of study
participants who provide whole genome
data. It is now apparent that someone with
access to an individual’s whole genome
genotype data can, in theory, determine
whether they were a member of a group
given just the aggregate (that is, summary
allele frequency) data for that group [3,4].
The authors of the study now reported [1]
have provided limited aggregate data
related to their statistically significant
genetic associations with traits, as they
implied they would in their consent
document, and we note that these data
are insufficient to identify participants.
Current policy of the NIH, Wellcome
Trust, and other large-scale public human
genotyping efforts is to restrict access to
individual genotypes to permitted expert
investigators,whileencouragingsubmission
of the individual profiles to public reposi-
tories. Such submission is precluded by the
consent obtained by 23andMe, and we
agree that it would be unreasonable to
require it. Individuals who voluntarily
participate in commercial-sponsored re-
search should not be asked to agree to have
their personal genomic data submitted to a
government-sponsored data repository, no
matter what access restrictions are current-
ly inplace.Havingpaid for the service, they
have a reasonable expectation that their
personal information will not be provided
to the general public without specific
consent. This places PLoS Genetics in the
position of promoting open access to the
research enterprise, buthaving todecideon
the appropriateness of publishing a study
where access is more restricted than usual.
In this decision, we must balance the public
good of open access to research with the
public good of disseminating valuable
science performed by commercial entities.
Noting that there is potential for access to
the underlying data for collaborators
through a re-consent process, on balance
we decided that the interests of presenting
the findings to the genetics community
favored publication of the study.
Summary Statement
The editors of PLoS Genetics recognize
that the decision to publish this study,
without IRB review as human subjects
research and with some concerns over the
consent document, and the fact that there
is limited access to the raw data, will not sit
well with some, perhaps many, readers. As
outlined above, though, a prima facie valid
IRB exemption was obtained, and, while
there are ambiguities in the consent form,
there was no evidence that these amount
to an inadequate document. After consid-
ering all of the evidence, we decided that
publication, accompanied by an editorial
providing transparent documentation of
the process of consideration, was the most
appropriate course.
In so doing, we call for community input
to spur efforts to standardize the IRB
consent process for GWAS research. With
a few exceptions, academic IRBs are not
typically constituted by geneticists and
certainly not by experts with expertise in
contemporary genomic profiling and all of
the issues it raises. Current practice follows
norms established in an era when studies
involved dozens, or maybe hundreds, of
participants and focused on one or a few
biomarkers. We now face the prospect in
the coming decade of whole-genome se-
quence data obtained for thousands of
individuals on standard individual–investi-
gator research grants. It is almost incon-
ceivable that even scientifically literate
members of the public will appreciate the
full implications of the provision of whole-
genome genetic data, yet we must trust
participants to make informed and sensible
decisions. At the same time, consent
documents necessarily simplify very diffi-
cult genetic issues that even experts dis-
agree over and use lay language that glosses
over technical matters. A good argument
can be made that the consent process
followed by 23andMe study participants,
presumably following considerable reflec-
tion, is more informed than most processes
that have been formally reviewed. Against
this background, we have had extensive
discussion with the authors of this study to
address our concerns and to update their
processes, but we anticipate broad evolu-
tion of GWAS consent and review in the
near future.
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